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Numerous studies have reported neuroprotective effects of pyruvate when given in 
systemic injections. Impaired glucose uptake and metabolism are found in Alzheimer’s 
disease (AD) and in AD mouse models. We tested whether dietary pyruvate supplemen-
tation is able to provide added energy supply to brain and thereby attenuate aging- or 
AD-related cognitive impairment. Mice received ~800 mg/kg/day Na-pyruvate in their 
chow for 2–6 months. In middle-aged wild-type mice and in 6.5-month-old APP/PS1 
mice, pyruvate facilitated spatial learning and increased exploration of a novel odor. 
However, in passive avoidance task for fear memory, the treatment group was clearly 
impaired. Independent of age, long-term pyruvate increased explorative behavior, which 
likely explains the paradoxical impairment in passive avoidance. We also assessed 
pyruvate effects on body weight, muscle force, and endurance, and found no effects. 
Metabolic postmortem assays revealed increased energy compounds in nuclear 
magnetic resonance spectroscopy as well as increased brain glycogen storages in the 
pyruvate group. Pyruvate supplementation may counteract aging-related behavioral 
impairment, but its beneficial effect seems related to increased explorative activity rather 
than direct memory enhancement.
Keywords: alzheimer’s disease, aging, memory, explorative activity, glycogen
inTrODUcTiOn
One characteristic metabolic change with aging is a blunted glucose response to stress, whether 
physical, emotional, or cognitive (Gold, 2005). This can be demonstrated as a mismatch between 
adrenaline (epinephrine) release and subsequent rise in blood glucose levels in aged rats com-
pared to young ones (Gold, 2005). On the one hand, the inability to maintain adequate blood 
glucose levels upon challenge may lead to insufficient supply of glucose to the brain and cogni-
tive impairment (McNay, 2005). On the other hand, acute glucose infusion has been shown to 
improve cognitive performance in both rats and humans, especially during a highly demanding 
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(due to difficulty or duration) task (Gold, 2005). The aging-
related susceptibility to episodes with insufficient brain glucose 
supply is further exacerbated by common age-associated 
conditions, such as treatment of type 2 diabetes with glucose 
lowering medications or Alzheimer’s disease (AD) associated 
with reduced levels of glucose transporter 1 and 3 (Liu et al., 
2008).
The brain has also a buffer system to counteract sudden 
decrease in glucose supply. The most important mechanism is 
glycogen storage in astrocytes (Bélanger et  al., 2011), although 
a recent study suggests that neurons are also capable of storing 
glycogen (Saez et  al., 2014). Recent experimental evidence has 
established that glycogenolysis in astrocytes is instrumental for 
some key functions of astrocytes. First, despite efficient uptake of 
neurotransmitter glutamate by GLT-1 transporter into astrocytes, 
about 15% of glutamate under this shuttle is used for energy and 
thus needs to be replenished. This is largely done by pyruvate 
carboxylase leading to oxaloacetate with further conversion to 
α-ketoglurate, which then leaves the tricarboxylic acid cycle 
(TCA) for conversion to glutamate (Hertz et al., 2015). The pro-
cess is largely abolished by inhibition of glycogenolysis (Hertz 
et  al., 2015). Second, accumulating evidence indicates that the 
energy for Na+K+-ATPase-mediated K+ uptake derives from 
astrocytic glycogenolysis (Hertz et al., 2015). Through these two 
mechanisms, astrocytic glycogen stores may play a pivotal role in 
controlling excitability of neighboring neurons. This propensity 
may explain the findings that inhibition of glycogenolysis impairs 
memory consolidation in neonatal chicks (Gibbs et al., 2007) and 
rats (Suzuki et al., 2011). Notably, astrocytic glycogen stores are 
highly dynamic and susceptible to depletion upon physiological 
challenge. For instance, one-night sleep deprivation in rats leads 
to ~40% depletion of brain glycogen levels, which recover after 
15 h of sleep (Kong et al., 2002). Thus, poor night sleep, a com-
mon nuisance at old age and especially AD, may lead to depleted 
astrocytic glycogen stores and thereby further impair memory.
Neurons are potentially capable of utilizing interstitial lactate 
as an alternate energy substrate to glucose (Schurr et al., 1988; 
Amaral, 2013; Ivanov et al., 2014), since even at rest conditions, 
the interstitial fluid in neocortex and hippocampus contains 
about 2–3 mM of lactate (Zilberter et al., 2010). However, recent 
direct in vivo measurements in freely moving rats revealed that 
glucose is preferentially utilized by neurons (Lundgaard et  al., 
2015), suggesting that lactate may be consumed under conditions 
of extreme energy demands (Dienel, 2012). Whereas pyruvate is 
the end product of glycolysis and thus a direct energy substrate 
for mitochondria, lactate needs to be first converted to pyruvate. 
The latter reaction depends on the availability of cytoplasmic 
NAD+, which may be compromised under metabolic crisis 
(Zilberter et  al., 2015). Pyruvate, and to a lesser extent lactate, 
incubation prior to glucose deprivation sustained synaptic and 
metabolic function in hippocampal slices in one study (Shetty 
et  al., 2012). Moreover, pyruvate exposure led to the enhance-
ment of glycogen stores with time, compared to glucose alone. 
Radiolabeled pyruvate given as a bolus injection could pass the 
blood–brain barrier (BBB) similarly to glucose and was detected 
in a large amount in the brain 5 min after the injection (Miller and 
Oldendorf, 1986; Gonzalez et al., 2005).
Multiple neuroprotective effects of pyruvate after systemic 
administration have been reported in animal models in the 
cases of brain injury (Fukushima et  al., 2009), ischemia (Kim 
et al., 2005; Yi et al., 2007), glutamate neurotoxicity (Miao et al., 
2011), hemorrhagic shock (Mongan et al., 2003; Su et al., 2013), 
hydrogen peroxide-induced cell death (Nakamichi et al., 2005), 
oxygen-glucose deprivation (Ryou et al., 2013), cognitive impair-
ment due to hypoglycemia (Suh et  al., 2005), ethanol-induced 
neurodegeneration (Ullah et al., 2013), and zinc-induced cortical 
neuronal death (Sheline et al., 2000). In addition, a recent study 
reported improved spatial memory in the Morris swim task in 
both 6- and 12-month-old 3xTg AD model mice after repeated 
i.p. pyruvate injections over months (Isopi et al., 2015).
We have recently reported that 5-week dietary supplementa-
tion with pyruvate +  β-hydroxybutyrate in the chow reversed 
impaired tolerance of APPswe/PS1dE9 mice to hypoglycemia, 
normalized their reduced brain glycogen stores, and attenuated 
their enhanced neuronal excitability both in  vitro and in  vivo 
(Zilberter et al., 2013). Our subsequent pilot studies showed that 
a similar effect can be obtained by pyruvate supplementation 
alone. These findings raised the question whether oral pyruvate 
supplementation could also provide a means to counteract aging 
and AD-related memory impairment as alluded to by the study 
in 3xTg mice (Isopi et  al., 2015). However, the previous study 
used only one behavioral assay (the Morris swim task) and only 
reported the number of platform crossings and latency in the 
probe trial without commenting eventual pyruvate effects on 
non-cognitive factors, such as swimming speed that may affect 
learning. Since the existing literature on pyruvate mainly focuses 
on its effects on muscle force and energy metabolism, we wanted 
to study not only cognitive effects of pyruvate but also its impact 
on non-cognitive factors, such as spontaneous activity, muscle 
force, endurance, and anxiety. To this end, we ran three separate 
experiments with a large behavioral test battery and assessed 
the direct effects of pyruvate substitution on the indices of brain 
energy metabolism. The first experiment was run in middle-aged 
wild-type mice and the second one in adult APPswe/PS1dE9 
(APP/PS1) mice that both show only modest memory impair-
ment compared to young adult mice (Minkeviciene et al., 2008). 
The third experiment addressing alternative non-cognitive 
mechanisms of pyruvate action was done in adult wild-type mice 
owing to the limited availability of older wild-type or APP/PS1 
mice and to clarify the observed consistency of pyruvate effects 
independent of age.
MaTerials anD MeThODs
animals
Experiment 1 comprised 36 male C57Bl/6J mice (breeding 
at Laboratory Animal Center, University of Eastern Finland, 
Kuopio, Finland) that started the dietary intervention at 6 months, 
behavioral testing at 12 months of age, and were euthanized when 
reaching 13 months. Experiment 2 comprised 25 male APPswe/
PS1dE9 transgenic mice (Jankowsky et  al., 2004) that started 
the dietary intervention at 4.5  months, behavioral testing at 
6.5 months of age, and were euthanized at the age of 7 months. 
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Experiment 3 comprised 20 male C57Bl/6J mice that started the 
dietary intervention at 3 months, behavioral testing at 5 months 
of age, and were euthanized at 6.5  months of age. In addition, 
another group of 19 male C57Bl/6J mice were tested with acute 
pyruvate vs. saline injection at the age of 5 months. The mice came 
from a local breeding colony at University of Eastern Finland 
that was based on breeder mice from Johns Hopkins University 
(Baltimore, MD, USA). The line was originally generated as 
C3H × C57Bl/6J hybrid but had been back-crossed to C57Bl/6J 
strain for 18 generations.
The animals were group-housed until the behavioral tests 
in controlled environment (temperature 22  ±  1°C, light 
0700–1900  hours, and humidity 50–60%), and food and water 
were freely available. All behavioral tests were conducted during 
the light phase. The experiments were conducted according to the 
Council of Europe (Directive 86/609) and Finnish guidelines and 
approved by the Animal Experiment Board of Finland.
Treatment
Chronic Pyruvate Administration
The test group (PYR) received experimental chow supplemented 
with 0.6% (w) of Na-pyruvate (Safe Diets, Augy, France). The 
control group (STD) received the same basic rodent chow (A04, 
Safe Diets). With the average food intake of 4 g, this corresponds 
to 800 mg of pyruvate/day, which is at the upper range of effec-
tive pyruvate doses in earlier in  vivo studies (Suh et  al., 2005; 
Fukushima et al., 2009; Isopi et al., 2015).
Acute Pyruvate Administration
The mice received Na-pyruvate (Sigma, St. Louis, MO, USA) 
500 mg/kg i.p. or the same molar concentration of NaCl (260 mg/
kg i.p.). This single dose affords neuroprotection against cortical 
concussion injury and increases brain glucose and pyruvate levels 
as measured by in vivo microdialysis (Fukushima et  al., 2009). 
All cage labels about the treatment groups were coded so that 
the researchers running behavioral tests or assays on postmortem 
samples were blinded as to the treatment.
Behavioral Testing
Morris Swim Task (Water Maze)
Spatial learning and memory was tested with Morris swim navi-
gation task. The apparatus consisted of a white plastic pool with 
diameter of 120 cm and of transparent platform (10 cm × 10 cm) 
submerged 1.0 cm below the water surface. Water temperature 
was kept at 20 ±  5°C throughout the testing, and 8–10  min 
recovery period in a warmed cage was allowed between all trials. 
Before actual navigation task, the mice were pretrained (2 days) 
to find and climb onto the submerged platform, aided by a guid-
ing alley (1 m × 14 cm × 25 cm) with opaque walls preventing 
any spatial clues to be seen. In the learning phase (days 1–4), five 
60-s trials per day were conducted with the hidden platform. The 
platform location was kept constant and the starting position 
varied between four constant locations at the pool rim, with all 
mice starting from the same position and nose pointing toward 
the wall in any single trial. If a mouse failed to find the escape 
platform within 60 s, it was placed on the platform for 10 s by 
the experimenter. Also, when mice found the platform inde-
pendently, they were allowed to stay on the platform for 10  s. 
On day 5, the last trial (fifth) was run without the platform to 
test the search bias that was followed for 60 s. The experimenter 
marked the start of each trial using a remote controller and the 
trial ended automatically when a mouse landed on the platform. 
Swim paths and other parameters were tracked and recorded by 
video tracking system EthoVision XT 7 (Noldus, Wageningen, 
Netherlands).
Wall-swimming tendency (thigmotaxis) was assessed by cal-
culating the time the mouse spent in the outer zone within 10 cm 
of the wall. The search bias during the probe trial was measured 
by calculating the time the mice spent in the vicinity of the former 
platform position. We defined this as a target area, centered on 
the platform, with a diameter of 30 cm. This target area comprised 
6.25% of the total surface, which means that a mouse swimming 
randomly in the pool would be expected to spend 3.75 s in the 
target area during the 60-s probe trial.
Odor Recognition Task
The task is based on individual specific odors of mice. Before the 
test, each mouse to be tested got two small (diameter 20 mm) odor-
less balls made of birch wood (Step Systems Oy, Lahti, Finland) 
on the cage bedding. Similarly, a specifically assigned odor donor 
mouse got several of these balls. These were left overnight to get 
impregnated with the mouse odor, and in the case of the test 
mice to let them get adopted to the presence of the balls in their 
home cage. The wooden balls were removed in the morning. After 
2–4 h, the mouse was presented with two balls, one impregnated 
with its own odor and the other one from the cage of the donor 
mouse. The test was replicated the next day with one ball of the 
mouse’s own odor and a second ball impregnated with the odor 
of another unfamiliar mouse. We measured the total time sniffing 
(the nose pointing to the ball at a distance <2 cm) during a 120-s 
test session. Only if the total sniffing time exceeded 10 s, we also 
counted the odor preference as the percent of total time that the 
mouse was sniffing the ball with unfamiliar odor.
Passive Avoidance
The test was conducted in a shuttle box (L 44 cm × W 17 cm × H 
25 cm; Med Associates Inc., St. Albans, VT, USA) that was divided 
by a partition into two halves. One half was open and well-lit, 
while the other half was closed by black plastic walls and cover 
plate. Both compartments had a similar grid floor. The partition 
had an arch-shaped 6 cm wide opening that could be closed by a 
slide door. On day 1, the mouse got first 5 min to freely explore 
both compartments. Then, the mouse was placed in the open 
compartment and the slide door was closed for 30 s. Once the 
door was opened, the experimenter took the time for the mouse 
to enter the dark compartment, closed the opening, and delivered 
two mild foot shocks (0.30 mA, 2 s, interval 2 s). After the foot 
shock, the mouse was immediately returned to its home cage. On 
day 2, the time to enter the dark compartment was measured with 
a stop watch until a cutoff time of 180 s. No shocks were delivered 
on day 2.
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Spontaneous Explorative Activity
Spontaneous explorative activity was assessed by using an 
automated activity monitor (TruScan, Coulbourn Instruments, 
Whitehall, PA, USA) based on infrared photo beam detection. The 
system consisted of an observation cage with white plastic walls 
(26 cm × 26 cm × 39 cm) and two frames of photo detectors ena-
bling separate monitoring of horizontal (XY-move time) and verti-
cal activity (rearing). The test cage was cleaned with 70% ethanol 
before each mouse to avoid odor traces. The following parameters 
were measured during a 10-min session: ambulatory distance 
(gross horizontal locomotion) and rearing time. The recording 
was repeated 48 h later to assess habituation to the environment.
Marble Burying Test
To assess neophobia and general housekeeping activity, the home 
cage floor was filled with double amount of clean bedding mate-
rial and nine glass marbles (diameter 1 cm) were inserted in a 
3 × 3 array onto the bedding. Visible marbles were then counted 
after 24 h.
Elevated Plus Maze
The maze, as the name implies, had a shape like a plus sign and 
consisted of a square platform (5  cm ×  5  cm) and four arms 
(30  cm ×  5  cm, two open and two closed), all made of black 
plastic but covered with white plastic to help video monitoring. 
The maze platform was 50  cm above the floor in a dimly lit 
room. Each mouse was placed on the center platform facing an 
open arm and allowed to explore the maze for 5 min. A video 
camera hanging from the ceiling recorded the session, which was 
analyzed offline with EthoVision XT 7 software. The time spent 
in the open and closed arms, the total distance, and speed in 30 s 
bins were calculated as well as the percentage of total time spent 
on the open arms to index anxiety. Only mice making more than 
five moves between arms during the test were included in the 
statistical analysis for % time on the open arms.
Open Field
The test was conducted in the dry pool (diameter 120 cm) used for 
Morris swim task. The mouse was placed in the arena center and 
its movement was recorded for 10 min. Using EthoVision XT 7 
software, we calculated the total distance traversed, speed in 30-s 
bins, and the % time spend in the arena center (diameter 40 cm).
Pain Threshold
The test was conducted 2 weeks after the passive avoidance test 
in the same apparatus. The mouse was first given 3 min to fully 
familiarize with the environment and calm down. Then, electric 
shocks were delivered every 30  s with gradually increasing 
intensity (0.05, 0.06, 0.08, 0.10, 0.12, 0.15, 0.2, and 0.3 mA) until 
the mouse reacted by jumping. Before that, the current intensity 
eliciting a startle response was also recorded.
Grip Force Test
The grip force was measure using a simple spring scale 
(Kouluelektroniikka Oy, Rauma, Finland) with a metal grid for 
the mouse to grip with both front paws. The scale was positioned 
at a 45° angle at the edge of a table. The mouse was gently pulled 
by the tail until it could no longer withhold the grip. The test was 
repeated five times every 30 s and the best reading was recorded.
Treadmill Test
The apparatus was a treadmill designed for mice (LE8710R, Bioseb, 
France) with adjustable speed and inclination. The mouse was 
motivated to keep running by a gentle electric shock (0.15 mA dur-
ing training and 0.2 mA during testing) at the proximal end of the 
belt. The mice were familiarized with the procedure in two 10-min 
sessions during 2 days. On the first day, the belt was rolling at a fixed 
speed of 15 cm/s; on the second day, the speed was increased gradu-
ally from 15 to 25 cm/s. On the test day, the speed of the belt was 
increased from 15 cm/s with a step of 5 cm/s every minute until the 
speed of 35 cm/s was reached. When the mouse took five electric 
shocks with 1-s intervals or made only minimum spurts to avoid the 
shocks, it was judged to be exhausted and the test was terminated.
Metabolic assays
Histochemical Assay – Periodic Acid Schiff Staining
In Experiment 1, after behavioral testing mice were deeply 
anesthetized with pentobarbiturate-chloral hydrate cocktail 
(60 mg/kg i.p. each) and perfused transcardially with 50-ml ice-
cold saline (10 ml/min) for 5 min. The brain was removed and 
split sagittally. The left hemisphere was immersion fixed in 4% 
paraformaldehyde for 4 h, transferred to a 30% sucrose solution 
overnight, and stored in a cryoprotectant in −20°C for later histol-
ogy. The hemisphere was cut on a freezing slide microtome into 
20-μm coronal sections. Periodic acid schiff (PAS) staining was 
done on two adjacent sections at the level of mid-hippocampus 
(A −2.7 from bregma) in eight STD mice and eight PYR mice. 
First, the sections were hydrated to water and after that oxidized 
in 0.5% periodic acid solution for 5 min. After rinsing in distilled 
water, the sections were soaked in Schiff reagent for 1 min. To get 
right dark pink color, sections were washed in lukewarm water 
for 5 min. Dehydration was done with rising alcohol series and 
coverslipping with DePeX mounting medium. Sections were 
photographed using the Zeiss Imager M2 microscope (Zeiss, 
Oberkochen, Germany) and the attached AxioCam ERc 5s cam-
era with a 2.5× objective. Images were transformed to grayscale 
in Photoshop CS6 software (Adobe Systems Inc., San Jose, CA, 
USA), which was also used for image analysis. The mean optic 
densities values (0 for black to 255 for white) were determined 
from four regions of interest: DG molecular layer, CA1 all layers, 
white matter (alveus + corpus callosum), and visual cortex.
Enzymatic Analysis of Glycogen Content
At the end of Experiment 3, five young adult mice on STD and 
five on PYR diet were euthanized with a microwave radiator 
(5 W, 0.85 s, Muromachi Kikai Co., Ltd., Tokyo, Japan) and the 
brains were removed, the cortex dissected out, and stored at 
–70°C. One STD mouse had to be discarded because of failed 
procedure. The quantitative amounts of glycogen in the tissue 
were assessed in a coupled enzymatic assay by measuring the 
production of NADPH in the conversion of glucose-6-phosphate 
to 6-phosphogluconolactone as described by Brown et  al. 
(2003). To prepare the samples for the assay, the tissues were 
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homogenized by sonication in ice-cold 70% ethanol. The samples 
were centrifuged at 20,000 × g for 10 min and the supernatant was 
discarded. The remaining pellet was washed twice with ethanol 
and once with water and resuspended in an acetate buffer (pH 
5). Aliquots of the homogenized pellets were adjusted to pH 2 
by the addition of HCl. Amyloglucosidase dissolved in an acetate 
buffer (pH 5) was added to the acidified homogenates before 
incubation at 37°C and 50  rpm for 1  h in an alkaline solution 
(37.1 mM Tris base, 0.007% sodium azide, and 13.8 mM HCl) to 
ensure pH 7–8, i.e., the pH optimum for hexokinase and glucose-
6-phosphate dehydrogenase. The reaction was initiated by the 
addition of hexokinase and glucose-6-phosphate dehydrogenase 
to final concentrations of 1.52 and 0.54 U/ml, respectively. The 
fluorescence was measured before addition of the enzymes and 
following 40 min of incubation at room temperature, using 360 
and 415 nm as excitation and emission wavelengths, respectively. 
Glucose in the concentration range of 20–200 μM was used as a 
standard, and the amount of glycogen in the samples is expressed 
as nanomoles of glucose per milligram of protein. The protein 
amounts in the samples were determined using the BCA method 
employing bovine serum albumin as standard.
1H NMR Analysis
After behavioral tests, mice of Experiment 2 (APP/PS1 mice at 
7 months of age) were euthanized with cervical dislocation, the 
brain was rapidly removed, frontal 1/3 was cut off and snap frozen 
in liquid nitrogen, and stored at –70°C. We chose a frontal cut 
instead of hippocampal preparation to keep the postmortem delay 
to the minimum (now 80–100 s). Weighed tissue samples were 
subjected to perchloric acid (PCA) extraction. The frozen tissue 
samples were transferred into a precooled mortar and grounded 
by a pestle with liquid nitrogen to fine powder. The ground tissue 
powder was transferred into a cold 2-ml Eppendorf tube, and 
1.0 ml of cold 0.9M PCA was added. The obtained suspension was 
homogenized by vortex mixing and sonication (15 min indirect 
sonication) in a water/ice bath. The supernatant was separated 
after centrifugation (10 min at 16,000 × g + 4°C) and neutralized 
using 2M potassium hydroxide. Precipitation (potassium perchlo-
rate) was removed by centrifugation (15 min at 16,000 × g + 4°C) 
and the obtained supernatant was freeze-dried. Prior to the NMR 
measurements, neutralized, freeze-dried PCA extracts were 
dissolved to deuterium oxide containing 200 μM sodium 3-(tri-
methylsilyl)propionate-2,2,3,3-d4 (TSP) as a reference substance.
1H NMR spectra of the extracted samples were recorded 
on a Bruker Avance III HD 600 NMR spectrometer operat-
ing at 600.28  MHz and equipped with a Prodigy TCI 5  mm 
cryogenically cooled probe head. Standard 1D 1H NMR spectra 
were recorded with 64k data points using 32 transients and 
applying a standard Bruker zg pulse sequence. The acquisition 
time was 4.3 s and the relaxation delay 5.7 s. The spectra were 
measured at 295 K. The free induction decays (FIDs) were mul-
tiplied by an exponential window function with a 0.3-Hz line 
broadening. Identification of the metabolite signals was based 
on the data in the literature (Govindaraju et al., 2000; de Graaf 
et  al., 2011) or in-house databases and spiking experiments. 
The quantification of the identified metabolites was done using 
quantitative quantum mechanical spectral analysis (qQMSA) 
approach with the program qQMTLS (Tiainen et al., 2014). The 
concentrations are reported as nanomole per milligram (wet 
tissue weight).
statistics
All statistics were calculated using IBM SPSS Statistics 19 software 
(IBM Corporation, NY, USA). Behavioral tests that were repeated on 
two or more days were analyzed by ANOVA for repeated measures 
using the diet as between-subject factor. Otherwise, the comparison 
of the diet groups was done with Student’s t-test, with the exception 
of passive avoidance for young animals where more than half of 
the animals reached the cutoff time. Here, non-parametric Mann–
Whitney test was applied. Data are expressed as group mean ± SEM. 
Threshold for statistical significance was set at p < 0.05.
resUlTs
experiment 1: chronic Pyruvate 
supplementation in Middle-aged Wild-
Type Mice
Improved Spatial Learning after Chronic Pyruvate
At 12 months of age (and after 6 months on test diet), spatial learn-
ing was tested in the Morris swim task. Mice on pyruvate supple-
mentation (PYR) acquired the task faster than mice on standard 
chow (STD) as evidenced by shorter escape latency across five test 
days (F1,34 = 7.3, p = 0.01; Figure 1A). PYR mice were also faster 
to quit the inefficient strategy to search for an escape through 
the pool wall (thigmotaxis) than STD mice (F1,34 = 4.6, p = 0.04; 
Figure  1B). Neither measure showed a diet ×  day interaction 
(escape latency, p = 0.15; thigmotaxis, p = 0.36). The last swim on 
day 5 was a probe trial without the platform to assess the spatial 
search bias. PYR mice tended to spend more time in the vicinity of 
the former platform position that STD mice, but the difference did 
not reach statistical significance (t34 = 1.6, p = 0.11; Figure 1C).
Improved task acquisition, but only a modest augmentation, of 
memory retention can imply faster learning but also some non-
cognitive effect of pyruvate supplementation, such as enhanced 
endurance in the swim task that is physically strenuous. To 
control this possibility, we compared swimming speeds between 
the groups. There was no overall difference in swimming speed 
across days (F1,34 = 0.5, p = 0.48). We also looked for the pos-
sibility of less fatigue on repeated trials in the PYR group, but a 
separate analysis of swimming speeds on the last trial of the four 
task acquisition days did not differ between the groups (p = 0.61).
Enhanced Odor Recognition but Impaired Fear 
Conditioning after Chronic Pyruvate
To assess the generalization of augmented learning effect of 
chronic pyruvate, the same 12-month-old mice were subjected 
to odor recognition and passive avoidance task. In the odor 
recognition task, the total sniffing time on day 1 was 45.8 ± 6.1 s 
(mean ± SEM) for STD mice and 57.1 ± 6.2 s for PYR mice, and 
on day 2, 42.3 ± 6.1 s for STD mice and 49.1 ± 6.0 s for PYR mice. 
There was no diet main effect on total sniffing time (F1,34 = 1.4, 
p = 0.24). However, the odor preference was significantly stronger 
across the two test sessions in PYR mice compared to STD mice 
(F1,30 = 4.7, p = 0.04; Figure 1D).
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FigUre 1 | Behavioral studies in 12-month-old wild-type mice treated with standard chow (sTD) or pyruvate-supplemented chow (PYr) for 
6 months. (a) Escape latency during 5 days of Morris swim task acquisition. PYR group differs from STD group on this day (*p < 0.05, t-test). (B) Time in the wall 
zone (10 cm wide). PYR group differs from STD group on this day (*p < 0.05, t-test). (c) Time in the platform zone (15 cm radius from the former platform center) 
during the probe test on day 5. (D) Time preference to explore the odor of an unknown mouse over one’s own odor on two test days. The dashed line indicates 
chance level (50%). PYR group differs from STD group across days (*p < 0.05, ANOVA-RM). (e) Step-through latency in the passive avoidance task, cutoff 180 s. 
Day 1 is the training day and day 2 the test day after fear conditioning. PYR group differs from STD group on day 2 (**p < 0.01, t-test). (F) Rearing time in the 
transparent novel test cage on days 1 and 3, test duration 10 min of each day. PYR group differs from STD group across days (*p < 0.05, ANOVA-RM). Group 
Means ± SEMs are shown.
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In the passive avoidance task, the groups did not differ in 
their latency to enter the dark compartment before conditioning 
(t34 = 1.8, p = 0.09), although mice in the PYR group tended to 
enter sooner than STD mice. However, after the fear conditioning, 
STD mice waited much longer than PYR mice before entering the 
dark compartment now associated with a foot shock (t34 = 3.3, 
p = 0.002; Figure 1E).
Increased Spatial Exploration but No Effect on 
Locomotion or Object Neophobia by Chronic 
Pyruvate
To better understand the ostensibly discrepant result of improved 
spatial learning and odor recognition but impaired retention of 
fear conditioning after chronic PYR administration, we ran a 
battery of control behavioral tasks to assess PYR effects on spon-
taneous exploration, locomotor activity, and object neophobia.
Although the ambulatory distance was slightly higher in 
the PYR group, the difference was not significant (F1,34 =  2.0, 
p = 0.17), and both groups showed robust reduction in the dis-
tance traversed during the second exposure to the novel test cage. 
In contrast, there was a significant difference in the rearing time 
between the groups (F1,34 = 6.4, p = 0.02), such that PYR mice 
spent more time rearing on both sessions (Figure 1F). Rearing is 
typically related to exploration of a new environment.
The marble burying test did not reveal significant differences 
in object neophobia between the diet groups. The STD mice left 
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FigUre 2 | Behavioral studies in 6.5-month-old aPPswe/ps1de9 mice treated with standard chow (sTD) or pyruvate-supplemented chow (PYr) for 2 
months. (a) Escape latency during 5 days of Morris swim task acquisition. (B) Time in the wall zone (10 cm wide). (c) Time in the platform zone (15 cm radius from 
the former platform center) during the probe test on day 5. (D) Time preference to explore the odor of an unknown mouse over one’s own odor on two test days. 
The dashed line indicates chance level (50%). PYR group differs from STD group across days (*p < 0.05, ANOVA-RM). (e) Step-through latency in the passive 
avoidance task, cutoff 180 s. Day 1 is the training day and day 2 the test day after fear conditioning. PYR group differs from STD group on day 2 (**p < 0.01, t-test). 
(F) Rearing time in the transparent novel test cage on days 1 and 3, test duration 10 min of each day. PYR group differs from STD group across days (*p < 0.05, 
ANOVA-RM). Group Means ± SEMs are shown.
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5.0 ± 0.5 marbles out of nine visible and the PYR mice 4.8 ± 0.5 
(p = 0.74).
experiment 2: chronic Pyruvate 
supplementation in 6.5-Month-Old  
aPP/Ps1 Mice
Modest Improvement in Spatial Learning after 
Chronic Pyruvate
At 6.5  months of age (and 2  months on test diet), the diet 
groups differed significantly in their swimming speed across 
all test days (STD group faster; F1,23 =  7.1, p =  0.01; data not 
shown). Therefore, the task acquisition was assessed by the swim 
path length. The path length did not differ between the groups 
(F1,23 = 1.0, p = 0.76; Figure 2A). No overall difference was found 
in the time spent in the wall zone, either (F1,23 = 0.5, p = 0.48; 
Figure  2B). However, the diet ×  day interaction approached 
significance for the path length (F4,92  =  2.2, p  =  0.08) and 
was significant for the time in wall zone (F4,92 = 2.6, p = 0.04; 
Figure  2B). In the probe test on day 5, PYR mice tended to 
swim more time in the vicinity of the former platform location 
(t23 = 1.8, p = 0.09; Figure 2C).
Enhanced Odor Recognition but Impaired Fear 
Conditioning after Chronic Pyruvate
In the odor recognition task, there was no diet main effect on total 
sniffing time (F1,23 = 0.1, p = 0.81). However, the odor preference 
was significantly stronger across the two test sessions in PYR mice 
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FigUre 3 | Behavioral studies in young adult wild-type mice. (a) Group 
means and individual values for step-through latency in the passive 
avoidance test run after chronic (2.5 months) dietary intervention. PYR group 
differs from STD group (*p < 0.05, Mann–Whitney U-test). (B) Running speed 
in the elevated plus maze plotted for each 30-s bin. During the first test half 
(2.5 min), mice on chronic PYR ran faster than STD mice (*p < 0.05, 
ANOVA-RM). (c) Group means and individual values for step-through latency 
in the passive avoidance test in the acute test groups. After the learning 
phase, half of the mice received Na-pyruvate at 500 mg/kg i.p., while other 
half received 260 mg/kg NaCl.
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compared to STD mice (F1,18 = 6.5, p = 0.02; Figure 2D). To be 
precise, on day 1, APP/PS1 mice on the STD diet actually showed 
aversion toward the odor of an unknown mouse, while showing 
no preference on day 2. In contrast, mice on PYR diet showed no 
preference on day 1 but a clear preference toward the novel odor 
on day 2 (Figure 2D).
In the passive avoidance task, the groups did not differ in 
their latency to enter the dark compartment before conditioning 
(t23 = 1.0, p = 0.35). However, after the fear conditioning, STD 
mice waited much longer than PYR mice before they entered the 
dark compartment now associated with a foot shock (t23 = 3.5, 
p = 0.002; Figure 2E).
Increased Spatial Exploration, No Effect on 
Locomotion but Decreased Object Neophobia by 
Chronic Pyruvate
The ambulatory distance did not differ between the diet groups 
(F1,23 = 0.3, p = 0.60), and both groups showed robust reduction 
in the distance traversed during the second exposure to the 
novel test cage. In contrast, there was a significant difference 
in the rearing time between the groups (F1,23 =  6.0, p =  0.02), 
such that PYR mice spent more time rearing on both sessions 
(Figure 2F). Rearing is typically related to the exploration of a 
new environment.
The pattern of behavioral effects of PYR was thus almost iden-
tical in 12-month-old wild-type mice and 6.5-month-old APP/
PS1 mice. The only notable differences were the acquisition phase 
of Morris swim task, where 6.5-month-old mice on PYR did not 
show improvement, and marble burying test, in which APP/PS1 
mice on PYR diet left more marbles visible than STD mice [STD: 
2.8 ± 0.4 marbles; PYR: 4.6 ± 0.6 (p = 0.03)].
experiment 3: Pyruvate supplementation 
in 5- to 6-Month-Old Wild-Type Mice
To shed light on the robust and reproducible finding that 
chronic PYR increased spatial learning and odor recognition 
but clearly impaired fear conditioning, we once again evaluated 
the possible non-cognitive effects of chronic PYR adminis-
tration in young adult wild-type mice (the same C57Bl/6J 
background as in APP/PS1 mice). First, at the age of 5 months 
(and 2 months on test diet), we repeated the passive avoidance 
task. The diet groups did not differ in their latency to enter the 
dark compartment before conditioning (t18 = 0.3, p = 0.76). In 
contrast to middle-aged wild-type or adult APP/PS1 mice, all 
but one young adult wild-type mouse in the STD group waited 
until the cutoff time before entering the dark compartment. 
However, in the PYR group, half of the mice entered before 
the cutoff time (p < 0.05, Mann–Whitney U-test, Figure 3A). 
So, the chronic pyruvate effect was present also in young adult 
wild-type mice.
To rule out a pyruvate effect on nociception, we measured the 
minimum current for the foot shock to elicit startle and jump 
responses. There was no effect of the diet on either the startle 
response (STD: 0.086 ± 0.003 mA; PYR: 0.083 ± 0.005; p = 0.60) 
or the jump response (STD: 0.21 ± 0.02 mA; PYR: 0.24 ± 0.02; 
p = 0.32).
To assess the potential role of PYR on anxiety, we ran the 
standard elevated plus maze test. PYR mice moved a longer 
distance during the 5-min test than STD mice (STD: 9.9 ± 0.4 m; 
PYR: 11.9 ±  0.5 m; t17 =  3.3, p =  0.004). A closer analysis on 
the running speed revealed that PYR mice run at a higher 
velocity during the first 2.5 min (F1,18 = 6.0, p = 0.025), but then 
the running speed became even between the treatment groups 
(p = 0.97; Figure 3B). However, the % time spent on open arms, 
which is considered the strongest indicator of anxiety in this 
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FigUre 4 | Metabolic assessment of brain glycogen levels. (a) Group means and individual values for cortical glycogen content in the enzymatic assay in 
young adult wild-type mice at 6 months of age after been on dietary intervention for 3 months by the time of euthanasia. PYR group has higher brain glycogen levels 
(*p < 0.05, t-test). (B) PAS staining for brain glycogen in 13-month-old wild-type mice been on the dietary intervention for 7 months. Data are given as relative optic 
density (OD%) with 0 corresponding to pure white and 100% to pure black. DG = dentate gyrus, molecular layer, CA1 = all layers of this subregion, 
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PAS-stained sections through the mid-hippocampus after conversion to grayscale. Scale bar = 500 μm. C = STD group and D = PYR group.
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task, did not differ between the diet groups (STD: 21.6 ± 3.5%; 
PYR: 26.6 ±  4.5%; t18 =  0.9, p =  0.40). We also ran the open 
field test as an additional measure of anxiety. The relative time 
spend in the field center during 10 min did not differ between the 
treatment groups (STD: 4.7 ± 0.7%; PYR: 4.5 ± 0.8%; t18 = 0.2, 
p = 0.86). However, we could see the same pattern as in elevated 
plus maze: PYR mice moved faster than STD mice during the 
first 2.5  min (F1,18 =  4.3, p =  0.05), but then the difference in 
running speed disappeared (p =  0.27, 0.38, and 0.33 for the 
remaining quartiles).
To assess whether long-term pyruvate administration directly 
affects muscle function, we measured maximum grip force and 
endurance on a treadmill. There was no difference in the grip 
force (STD: 1103 ± 36 N; PYR: 1127 ± 41 N, p = 0.66) or the 
time until exhaustion on the treadmill (STD: 33.6 ± 6.7 min; PYR: 
35.7 ± 6.1 min, p = 0.83).
Finally, we tested in another batch of young adult wild-type 
mice whether acute post-trial injection of Na-pyruvate (500 mg/
kg i.p.) would also impair retention of fear conditioning in the 
passive avoidance task. There was no difference between the treat-
ment groups either in the baseline latency (t16 = 0.5, p = 0.62) 
or latency 24 h after the fear conditioning (t16 =  1.0, p =  0.33; 
Figure 3C). This finding speaks against the possibility that PYR 
would have impaired memory consolidation.
Metabolic Effects of Chronic Pyruvate 
Supplementation
Among the middle-aged wild-type mice, the PYR group started 
with a lower body mass but gained more weight during the 
7  months on special diet, resulting in a significant diet ×  age 
interaction (F7,28 = 5.0, p = 0.001). At the end of the study, the 
body weights for STD mice were 38.8 ± 1.0 g and for PYR mice 
39.8 ± 0.9 g, p = 0.48. Similarly, among the young adult APP/
PS1 mice, the PYR mice tended to gain more weight during 
3 months on the special diet (F2,22 =  2.8, p =  0.08; end weight 
STD: 30.2 ± 0.6 g, PYR: 30.8 ± 0.7 g). On the other hand, no extra 
weight gain was observed in young adult wild-type mice on PYR 
diet (F1,18 = 0.1, p = 0.77).
To further evaluate the impact of chronic PYR supplementa-
tion on brain energy reserves, we euthanized nine young adult 
wild-type mice of Experiment 3 with microwaves and measured 
the cortical glycogen content. It was higher in the PYR group 
than in the STD group (t7 = 3.3, p = 0.01; Figure 4A). We also 
stained brain sections from a subset of 16 middle-aged wild-type 
mice for PAS to visualize brain glycogen. The optic density for 
PAS was significantly higher in PYR mice than STD mice in 
the dentate gyrus (p = 0.01), CA1 (p = 0.005) but not in alveus/
corpus callosum (p =  0.11) or overlying neocortex (p =  0.08) 
(Figures 4B–D).
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FigUre 5 | 1h-Mrs analysis of snap frozen brains of 7-month-old 
aPPswe/Ps1de9 mice been on the dietary intervention for 3 months 
by the time of euthanasia. (a) Cre = creatine/creatine phosphate, 
Lac = lactate, Myo = myoinositol, NAA = N-acetyl-aspartate, 
Gln = glutamine, Glu = glutamate, and Taur = taurine. (B) ADP = adenosine 
diphosphate, ATP = adenosine triphosphate, NAD = nicotinamide adenine 
dinucleotide, Ala = alanine, Asp = aspartate, Cho = choline, Gly = glysine, 
and GABA = gamma-amino butyric acid. PYR group differs from STD group 
at *p < 0.05 and **p < 0.01 (t-test).
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The brains of APP/PS1 mice were snap frozen in liquid 
nitrogen at the end of the study and assessed with 1H-MRS. As 
summarized in Figure  5, levels of several energy metabolites, 
such as creatinine, glutamate, and lactate, were increased in the 
PYR group compared to STD group. Collectively, these findings 
support the idea that long-term dietary supplementation with 
pyruvate increases brain energy reserves.
DiscUssiOn
The present study demonstrated that chronic dietary supple-
mentation with pyruvate (PYR) in mice results in behavioral and 
metabolic changes in the brain. The pattern of behavioral out-
comes was consistent between two independent experiments, one 
in 12-month-old wild-type mice and another in 6.5-month-old 
APP/PS1 mice. Long-term PYR supplementation (1) improved 
learning of the Morris swim task but did not significantly improve 
spatial memory as assessed by the search bias in the probe task, 
(2) enhanced preference to explore a novel odor, (3) increased 
rearing in a novel environment, and (4) robustly impaired 
performance in the passive avoidance task. The last effect could 
be observed in 5- to 6-month-old wild-type mice as well after 
chronic PYR supplementation but not after an acute post-
training injection. A common denominator to all these effects 
is the enhanced exploratory activity, which is consistent with the 
observed increase in rearing in a new test cage in the PYR groups 
and increased running speed in a new environment in a set of 
controls studies. Finally, by using three different methods, we 
could detect increases in the brain energy metabolism after PYR 
supplementation confirming that even oral PYR administration 
can affect the brain energy status provided that the duration of the 
treatment is long enough.
improved spatial Memory and Odor 
recognition
The first behavioral finding, decreased escape latency in the Morris 
swim task by middle-aged wild-type mice on PYR supplementa-
tion, and a trend toward a better search bias in the probe task are 
in line with the recent findings in 3xTg mice showing improved 
spatial search bias by PYR treatment both at 6 and 12 months of 
age (Isopi et al., 2015). Unfortunately, Isopi et al. did not show the 
results of the acquisition phase in their report, making the direct 
comparison between the studies difficult. On the other hand, 
we did not find significant improvement in spatial search bias 
in 6.5-month-old APP/PS1 mice. Unfortunately, due to time and 
budgetary restrictions, we could not let our APP/PS1 mice age 
beyond 6.5 months of age when the spatial learning impairment 
is still modest. Thus, we cannot exclude the possibility that PYR 
supplementation would have been beneficial in 12-month-old 
APP/PS1 mice with more robust memory impairment. Why the 
effect was particularly pronounced during the acquisition phase 
and not during the probe test? Morris swim task is a very complex 
task and changes in many aspect of the behavior may lead to faster 
task acquisition. At least we could rule out the simple explanation 
that PYR worked against fatigue and slower swimming speed that 
would automatically lead to longer escape latencies. There was 
no difference in swimming speed among middle-aged wild-type 
mice overall, and importantly, not during the last trial of the day 
when the mice should have showed fatigue. It is worth noticing 
that we let the animals recover and warm up for 10 min between 
the trials to avoid hypothermia that easily develops in mice dur-
ing swimming (Iivonen et  al., 2003). Improved learning could 
also be seen in terms of decreased thigmotaxis, tendency for 
searching escape through the pool wall. This can be interpreted 
as improved cognitive flexibility (abandoning of an inefficient 
strategy) or decreased fear to move from the wall to the pool 
center. Together, these facts suggest that the treatment effects are 
more likely mediated by altered brain function rather than altered 
muscle function.
The odor recognition task has proven to be sensitive to age-
dependent cognitive impairment in APP/PS1 mice (Koivisto 
et al., 2014). The task is based on the innate tendency of mice 
to explore a novel odor more than a familiar one. Not only 
should the mouse be familiar with its own odor but also to 
the presence of the wooden balls in its home cage during the 
familiarization phase. We cannot exclude the possibility that 
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reduced exploration of a novel behaviorally meaningful odor 
stems from impaired olfaction, but in other tests, APP/PS1 mice 
have shown no impairment in habituation to the odor ball upon 
repeated exposures or learning to associate the odor of a natural 
extract to the presence of odorless food reinforcement. However, 
the test is not a pure recognition memory, either, since the 
outcome is also influenced by the interest to explore novelty vs. 
fear for an unknown smell. Interestingly, PYR supplementation 
led to significant improvement in the task in both middle-aged 
wild-type mice and adult APP/PS1 mice similar to our recent 
finding in middle-aged APP/PS1 mice after dietary supplemen-
tation with the omega-3 fatty acid DHA (Koivisto et al., 2014). 
However, the young adult APP/PS1 mice also showed a clear 
fear-related aversion toward the unknown conspecific on the 
first test day but no more on the second day. The most likely 
explanation for the pattern (which to a smaller extend could 
be seen in middle-aged wild-type mice as well) is that we see 
a combined effect of two factors: repetition-dependent fear for 
the unknown odors and PYR-induced increased tendency for 
exploration.
Paradoxical impairment in Passive 
avoidance
The most consistent finding across age groups was the impair-
ment in passive avoidance task. At first, it seems counterintuitive 
to see “memory improvement” in two behavioral tasks by PYR 
supplementation, but then a robust “memory impairment” 
in a third classic memory task. Further, an impaired memory 
consolidation would be unexpected, since both glucose (Gold, 
2005) and lactate (Suzuki et  al., 2011) given as post-training 
injections have been reported to enhance memory retention in 
this task. Consistent with this, we did not observe impairment 
after post-training injection of PYR at the dose shown effective 
in several previous studies (Lee et  al., 2001; Suh et  al., 2005; 
Isopi et al., 2015). However, passive avoidance is known to be 
a “quick and dirty” task with several behavioral confounds. We 
could rule out the possibility that PYR supplementation affects 
pain threshold. Decreased level of anxiety could easily mask 
the effect of fear conditioning and encourage the animal to 
enter the dark compartment. However, we did not find much 
evidence for PYR-induced anxiolysis. Although the marble 
burying task revealed a response that could be interpreted as 
anxiolytic, this was only seen in APP/PS1 mice and not in the 
middle-aged wild-type mice with PYR treatment. Further, the 
classic anxiety tests parameters, relative time spent on the open 
arms in the elevated plus maze or time in the center of the open 
field, were not influenced by PYR supplementation. The best 
explanation we can offer for the time being is that chronic PYR 
increased exploration of novelty, leading to the situation where 
the drive for exploration weighed more than the fear for the foot 
shock. In fact, increased exploration provides the best possible 
explanation to all present behavioral findings (less thigmotaxis 
and faster learning in the Morris swim task, increased explora-
tion of a novel odor, increased rearing in a novel test cage, and 
increased running speed in the plus maze or open field during 
the first 2.5 min).
Direct Pyruvate effect or secondary after 
conversion to lactate in the liver?
The chow containing 6  g/kg pyruvate led to an average daily 
ingestion of 800 mg/kg/day after adjusting for food intake and 
spillage. Extrapolating to humans, these doses correspond to 
~10 g daily pyruvate intake. A recent study showed that a single 
pyruvate dose of 0.1  g/kg resulted in a shift in fuel utilization 
toward accelerated carbohydrate oxidation lasting for several 
hours (Olek et al., 2015). In rodents, the neuroprotective effects 
of intraperitoneal pyruvate have been reported for doses ranging 
from 200 to 1000 mg/kg [for review, see Zilberter et al. (2015)]. 
The dose of pyruvate used in this study proved to be efficient; 
however, it is yet unclear what amount of pyruvate actually enters 
the brain at chronic oral administration. One can suggest that 
pyruvate may first be converted to lactate in the liver before it 
enters the brain. It has been shown, however, that glucose but 
not lactate is a preferred fuel for neurons in  vitro (Patel et  al., 
2014), ex vivo (Ivanov et al., 2014), and in vivo in freely moving 
mice (Lundgaard et al., 2015). Meanwhile, the concentration of 
lactate in the extracellular cerebral fluid is close to that of glucose, 
and in the cortex is about 2–3 mM (Zilberter et al., 2010). Why 
then lactate is not utilized efficiently in spite of its relatively 
high level? We speculate that in the absence of extreme energy 
demands, the balance (presumably the redox state) is shifted 
toward glycolysis and subsequent release of excessive lactate from 
neurons (Dienel, 2012). In contrast, pyruvate is a “direct” energy 
substrate for mitochondria, while lactate needs to be converted 
first to pyruvate in the reaction dependent on the availability of 
cytoplasmic NAD+. In addition, besides being a mitochondrial 
fuel, pyruvate possesses a whole array of neuroprotective proper-
ties (Zilberter et al., 2015) lacking for lactate. A recent study on 
rats with Aβ microinfusion (i.c.v.) reported beneficial effects of 
pyruvate (500 mg/kg) after 10 daily intraperitoneal injections on 
spatial learning, LTP, ROS production, and neuronal survival. 
Corresponding effects were not obtained by systemic lactate 
injections, speaking for a direct pyruvate effect on neurons 
(Wang et al., 2015).
One may wonder why we did not find increased brain levels 
of pyruvate in the MRS assay. This is probably due to rapid pyru-
vate transformation to lactate. The kinetics of BBB transport of 
pyruvate is estimated to be 30- to 100-fold slower than the rate 
of pyruvate to lactate conversion. A recent MRI study employing 
hyperpolarized 13C-pyruvate could demonstrate the BBB pen-
etration of a small bolus injection pyruvate and its conversion to 
lactate within 2 min in the brain (Hurd et al., 2010). A massive i.p. 
injection of 1000 mg/kg in an in vivo microdialysis study resulted 
in increased pyruvate levels in the plasma and interstitial fluid for 
60 min, while the increased lactate levels were maintained for the 
entire 75-min follow-up time (Fukushima et al., 2009). Indeed, we 
could also detect increased levels of lactate in the brain, as well as 
those of glutamate and creatine/creatine phosphate. Considering 
that the mice were euthanized between 8:00 and 11:00 a.m. at 
least a couple of hours after significant ingestion of the chow 
during the dark period, it would have been impossible to even 
detect increased pyruvate levels in the circulation according to 
the microdialysis data. Thus, we must leave open the possibility 
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that a fraction of pyruvate, when administered orally, may first be 
converted to lactate in the liver before it enters the brain.
In any event, we could confirm our previous finding that 
pyruvate as dietary supplement is able to increase brain glycogen 
levels (Zilberter et al., 2013). At this point, we cannot say whether 
the observed behavioral changes were directly linked to increased 
glycogen stores or whether increased brain glycogen only acts as a 
surrogate marker for improved brain energy status. Anyway, sev-
eral neuronal processes have been shown to depend on astrocytic 
glycogen as their primary energy source. First, neurotransmitter 
glutamate is largely recycled, but ~15% is used for energy and 
needs to be replenished. This is mainly done by pyruvate car-
boxylase, which largely depends on glycogenolysis (Hertz et al., 
2015). Second, the energy for Na+, K+-ATPase-mediated K+ 
uptake into astrocytes after prolonged neuronal activity derives 
from astrocytic glycogenolysis (Hertz et al., 2015). Third, inhibi-
tor of glycogen phosphorylase inhibits memory consolidation in 
neonatal chicks (Gibbs et al., 2007) and rats (Newman et al., 2011; 
Suzuki et al., 2011).
indications for Pyruvate supplementation
Besides emergency medicine, pyruvate has been extensively stud-
ied in sports medicine for its possible effects to improve muscle 
mass and endurance. Some studies have reported enhanced 
exercise endurance capacity by oral pyruvate combined with dihy-
droxyacetone (Stanko et al., 1990a,b) and enhanced fat loss when 
combined with low-energy diet (Stanko et al., 1992). However, in 
one study, the combination of pyruvate with creatine increased 
anaerobic performance while pyruvate supplementation alone 
was ineffective (Stone et al., 1999). Similarly, oral pyruvate alone 
for a week (Morrison et al., 2000) or in combination with creatine 
(Van Schuylenbergh et al., 2003) was ineffective to improve aero-
bic performance in cyclists, and 30-day puruvate supplementation 
failed to increase aerobic exercise performance in untrained sub-
jects (Koh-Banerjee et al., 2005). Our findings in young adult mice 
are in line with these results, in that long-term pyruvate did not 
increase aerobic endurance or maximal anaerobic muscle force. 
At present, pyruvate supplements (creatine pyruvate) are actively 
marketed to body builders. The present study suggests a new indi-
cation for pyruvate by showing that dietary supplementation of 
pyruvate may offer a simple and effective way to correct for insuf-
ficient glucose supply and depleted glycogen stores in the aging 
brain. In addition to energy supplementation, pyruvate is a potent 
antioxidant, has anti-inflammatory, and anti-epileptic properties 
(Zilberter et al., 2015). It is well tolerated: up to millimolar plasma 
concentrations after i.v. infusion are reported not to have apparent 
adverse effects in humans (Dijkstra et al., 1984).
cOnclUsiOn
Long-term dietary supplementation of pyruvate led to clear 
behavioral changes. Improved spatial learning, increased explo-
ration of a novel odor, and a novel environment were seen in 
middle-aged wild-type mice as well as in adult APP/PS1 mice. 
The most consistent finding in all subgroups of mice was a shorter 
latency to enter the dark compartment in the passive avoidance 
task, which can be attributed to the increased drive for explora-
tion. We found no evidence that pyruvate would act by changing 
muscle force or endurance. Increases in brain energy metabolites 
and glycogen stores after long-term pyruvate supplementation 
also speak for an effect on the brain metabolism. Dietary pyru-
vate supplementation may prove beneficial against aging-related 
cognitive impairment and inactivity.
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